Efficient Correction of the Sickle Mutation in Human Hematopoietic Stem Cells Using a Cas9 Ribonucleoprotein Complex

Sickle Cell Disease (SCD) is a serious recessive genetic disorder caused by a single nucleotide polymorphism (SNP) in the ß-globin gene (HBB). Sickle hemoglobin polymerizes within red blood cells (RBCs), causing them to adopt an elongated “sickle” shape. Sickle RBCs damage vasculature, leading to severe symptoms, ultimately diminishing patient quality of life and reducing lifespan. Here, we use codelivery of a pre-formed Cas9 ribonucleoprotein complex (RNP) and a singlestranded DNA (ssDNA) oligonucleotide donor to drive sequence replacement at the SCD SNP in human CD34+ hematopoietic stem/progenitor cells (HSPCs). Corrected HSPCs from SCD patients produce less sickle hemoglobin protein and correspondingly increased wild-type hemoglobin when differentiated into erythroblasts. When injected into immunocompromised mice, treated HSPCs maintain editing long-term at therapeutically relevant levels. These results demonstrate that the Cas9 RNP/ssDNA donor approach can mediate efficient HSPC gene editing and could form the basis for treatment of SCD by autologous hematopoietic cell transplantation.

[1]  Caroline M. Watson,et al.  What is CRISPR/Cas9? , 2016, Archives of Disease in Childhood: Education & Practice Edition.

[2]  J. Corn,et al.  The Asymmetric Interaction of Cas9 with Target DNA can Promote High Efficiency Homology‐Directed Genome Editing , 2016, The FASEB Journal.

[3]  P. Gregory,et al.  Homology-driven genome editing in hematopoietic stem and progenitor cells using zinc finger nuclease mRNA and AAV6 donors , 2015, Nature Biotechnology.

[4]  S. Forman,et al.  Hematopoietic Cell Transplantation , 2015 .

[5]  A. Scharenberg,et al.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template , 2015, Science Translational Medicine.

[6]  Matthew C. Canver,et al.  BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis , 2015, Nature.

[7]  Xiquan Liang,et al.  Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. , 2015, Journal of biotechnology.

[8]  Jennifer A. Doudna,et al.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.

[9]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[10]  Wei Yan,et al.  Production of Gene‐Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation , 2015, Stem cells.

[11]  Jacqueline Corrigan-Curay,et al.  Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  Lei Zhang,et al.  Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. , 2015, Blood.

[13]  Ademola Samson Adewoyin,et al.  Management of Sickle Cell Disease: A Review for Physician Education in Nigeria (Sub-Saharan Africa) , 2015, Anemia.

[14]  Steven Lin,et al.  Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.

[15]  Steven Lin,et al.  Author response: Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014 .

[16]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[17]  G. Sauvageau,et al.  Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal , 2014, Science.

[18]  Meagan E. Sullender,et al.  Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation , 2014, Nature Biotechnology.

[19]  M. van der Burg,et al.  Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.

[20]  H. Kim,et al.  A guide to genome engineering with programmable nucleases , 2014, Nature Reviews Genetics.

[21]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[22]  J. Keith Joung,et al.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.

[23]  Gang Bao,et al.  CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity , 2013, Nucleic acids research.

[24]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[25]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[26]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[27]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[28]  J. Panepinto,et al.  Health‐related quality of life in sickle cell disease: Past, present, and future , 2012, Pediatric blood & cancer.

[29]  Ran Kafri,et al.  Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. , 2012, Molecular cell.

[30]  N. Copeland,et al.  Bcl11a is required for neuronal morphogenesis and sensory circuit formation in dorsal spinal cord development , 2012, Development.

[31]  Jianzhu Chen,et al.  Engineering humanized mice for improved hematopoietic reconstitution , 2012, Cellular and Molecular Immunology.

[32]  Igor Jurisica,et al.  Isolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment , 2011, Science.

[33]  F. Bushman,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[34]  S. Orkin,et al.  Update on fetal hemoglobin gene regulation in hemoglobinopathies , 2011, Current opinion in pediatrics.

[35]  Anthony E. Boitano,et al.  Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells , 2010, Science.

[36]  Marius Wernig,et al.  Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.

[37]  I. Weissman,et al.  Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. , 2007, Cell stem cell.

[38]  M. Gladwin,et al.  Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis , 2007, British journal of haematology.

[39]  M. Clarke,et al.  Hematopoietic stem cell self-renewal. , 2006, Current opinion in genetics & development.

[40]  Cage S. Johnson,et al.  Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients , 2005, Medicine.

[41]  Laurent Kiger,et al.  Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells , 2005, Nature Biotechnology.

[42]  Allen R. Chen,et al.  Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[43]  Takuro Nakamura,et al.  Bcl11a is essential for normal lymphoid development , 2003, Nature Immunology.

[44]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[45]  K. Sullivan,et al.  Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[47]  S. Clark.  An early death. , 1994, The American journal of medicine.

[48]  S. Davies,et al.  Bone marrow transplantation for sickle cell disease. , 1993, Archives of disease in childhood.

[49]  R. Huntsman.  Hemoglobinopathies , 1974, Bone Marrow Transplantation.

[50]  O. Correspondent.  Nucleases , 1967, Nature.

[51]  R. Verwilghen,et al.  Intravascular Haemolysis , 1962 .

[52]  L. Pauling,et al.  Sickle cell anemia a molecular disease. , 1949, Science.

[53]  J. Neel.  The Inheritance of Sickle Cell Anemia. , 1949, Science.

[54]  C. Delaney.  Expansion of Human Hematopoietic Stem Cells , 2016 .

[55]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[56]  Thomas Helleday,et al.  Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. , 2004, Nucleic acids research.

[57]  Gene Expression (1086 articles) , 2004 .

[58]  A. Dimovski.  Factors affecting the fetal hemoglobin levels in patients with sickle cell anemia and thalassemia , 1993 .

[59]  J. Stuart,et al.  Management of sickle-cell disease , 1974, Journal of clinical pathology. Supplement.

[60]  J. P. Lewis,et al.  HAEMATOPOIETIC STEM CELLS. , 1964, Nature.